India's NIFTY metal index rose by 1.25%.The Shanghai Stock Exchange approved the refinancing of Dizhe Medicine to support the development of new quality productivity. The announcement of Dizhe Medicine shows that the private placement plan of Dizhe Medicine in science and technology innovation board has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of unprofitable enterprises in Shanghai Stock Exchange has been approved since the issuance of the Eight Measures on Deepening science and technology innovation board's Reform, Service, Scientific and Technological Innovation and Development of New Productivity by CSRC. As a listed company with the fifth standard in science and technology innovation board, Dizhe Medicine's refinancing has been approved by Shanghai Stock Exchange, which reflects the institutional inclusiveness and support of the capital market for supporting new quality productivity and unprofitable technology-based enterprises with key core technologies, great market potential and outstanding scientific and technological attributes. Dizhe Medicine said that the company's refinancing will help the company to further accelerate product research and development and production base construction, create new quality productivity, implement major national strategies, promote products to the sea, and give scientific and technological impetus to the development of biomedical economy. (Sina Technology)Kremlin: (When asked whether the fall of Assad weakened Russia's influence in the Middle East) Military action in Ukraine is a top priority.
AIA: It cost about HK$ 62.73 million to buy back nearly 1.07 million shares. AIA Holdings Limited announced that it spent about HK$ 62.73 million to buy back about 1.07 million shares that day, accounting for 0.0098% of the issued shares, and the repurchase price per share ranged from HK$ 563,84942 to HK$ 598,0954.India's new central bank governor: policy stability is very important and will try to maintain policy continuity.MONDELEZ's share price rose 2.5% before the market, and it was authorized to buy back $9 billion in the news.
The Shanghai Stock Exchange approved the refinancing of Dizhe Medicine to support the development of new quality productivity. The announcement of Dizhe Medicine shows that the private placement plan of Dizhe Medicine in science and technology innovation board has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of unprofitable enterprises in Shanghai Stock Exchange has been approved since the issuance of the Eight Measures on Deepening science and technology innovation board's Reform, Service, Scientific and Technological Innovation and Development of New Productivity by CSRC. As a listed company with the fifth standard in science and technology innovation board, Dizhe Medicine's refinancing has been approved by Shanghai Stock Exchange, which reflects the institutional inclusiveness and support of the capital market for supporting new quality productivity and unprofitable technology-based enterprises with key core technologies, great market potential and outstanding scientific and technological attributes. Dizhe Medicine said that the company's refinancing will help the company to further accelerate product research and development and production base construction, create new quality productivity, implement major national strategies, promote products to the sea, and give scientific and technological impetus to the development of biomedical economy. (Sina Technology)At the opening of the night session, the main contract of No.20 glue rose by nearly 2%, and the main contracts of low sulfur fuel oil (LU) and coking coal rose by over 1%. In terms of decline, the main contract of alumina fell by more than 1%, and the main contract of palm oil and soybean meal fell by nearly 1%.Kremlin: Many people predict that Biden's administration will try to leave a difficult legacy by escalating tensions with Russia.
Strategy guide 12-14
Strategy guide
12-14
Strategy guide
Strategy guide 12-14
Strategy guide
12-14
Strategy guide